Molecular predictors of the outcome of paclitaxel plus carboplatin neoadjuvant therapy in high-grade serous ovarian cancer patients.
Anna P SokolenkoTatiana V GorodnovaIlya V BizinEkaterina Sh KuliginaKhristina B KotivAlexandr A RomankoTatiana I ErmachenkovaAlexandr O IvantsovElena V PreobrazhenskayaTatiana N SokolovaRobert V BroydeEvgeny N ImyanitovPublished in: Cancer chemotherapy and pharmacology (2021)
This study describes a cost-efficient method of detecting the BRCAness phenotype, which is compatible with the laboratory-scale NGS equipment. Some molecular predictors allow the identification of potential non-responders to paclitaxel plus carboplatin, who may need to be considered for other treatment options.
Keyphrases
- high grade
- end stage renal disease
- low grade
- ejection fraction
- chronic kidney disease
- phase ii study
- newly diagnosed
- lymph node
- rectal cancer
- prognostic factors
- locally advanced
- clinical trial
- radiation therapy
- phase iii
- patient reported outcomes
- mesenchymal stem cells
- risk assessment
- patient reported
- climate change
- chemotherapy induced
- smoking cessation